Modalis Therapeutics Corporation (JP:4883) has released an update.
Modalis Therapeutics Corporation will present advancements in the manufacturing of muscle-specific AAV vectors for epigenome editing therapies at the 16th Annual Bioprocessing Summit. These developments are crucial for the clinical trial production of MDL-101, a promising treatment for LAMA2-Congenital Muscular Dystrophy. The company’s proprietary CRISPR-GNDM technology is at the forefront of creating precision genetic medicines for rare genetic diseases.
For further insights into JP:4883 stock, check out TipRanks’ Stock Analysis page.
